Delving into the Latest Updates on Upadacitinib hemihydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Upadacitinib Hydrate, Upadacitinib tartrate, 乌帕奴单抗

+ [8]

Target

JAK1

Action

inhibitors

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [7]

Active Indication

Alopecia AreataNonsegmental vitiligoGiant Cell Arteritis+ [24]

Inactive Indication

Adenosine deaminase deficiencyDyssomniasLupus Nephritis+ [2]

Originator Organization

AbbVie, Inc.

Active Organization

AbbVie, Inc.AbbVie Ltd. (South Korea)

AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd.

+ [7]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (16 Aug 2019),

Rheumatoid Arthritis

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Special Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC34H40F6N12O3

InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N

CAS Registry2050057-56-0

ReCOUP is a multicenter clinical study designed to evaluate the efficacy of upadacitinib (Rinvoq®) in patients with ulcerative colitis whose disease has become active again despite maintenance treatment with upadacitinib 30 mg.
This study involves adult patients aged 18 to 64 years with active ulcerative colitis, who are being treated with upadacitinib and are not participating in another interventional clinical trial.
Participation in this study will depend on the patients' response to treatment during the 52-week maintenance period.
Several follow-up visits will be scheduled throughout the study according to a timetable defined by the protocol, and additional visits may be arranged if necessary depending on patients' health status.

Start Date15 Nov 2026

Sponsor / Collaborator

Getaid

NCT07670156

/ Not yet recruitingPhase 1/2IIT

Safety and Efficacy of Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

This study focuses on a genetic condition that affects the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) immune signaling pathway. A specific change in the DNA leads to overactivation of this pathway, which can result in immune dysregulation and related clinical symptoms.
Currently, five genetic mutations are known to cause these JAK-STAT pathway driven immune disorders: STAT1, STAT3, STAT5B, STAT6, and JAK1 (collectively referred to as JAK-STAT disorders). This study is a basket clinical trial, meaning patients with these different but related genetic conditions are enrolled in the same study and treated with the same investigational therapy.
The purpose of this study is to evaluate the safety and tolerability (ability to tolerate) of a drug called Upadacitinib in patients with JAK-STAT disorders with activating mutations. This drug belongs to a class of drug called Janus kinase (JAK) inhibitors, also known as JAKinibs. It is a type of immune system modulating medication that regulates (fixes) the JAK- STAT signaling pathway. Upadacitinib has been approved by the FDA for multiple immunological diseases and disorders. Presently, there is no FDA approved treatment for this group of JAK-STAT disorders. The study will also investigate immune factors in the blood to develop diagnosis methods that can be used in the future for better medical management of these disorders.
The study consists of four phases: screening phase, open label phase, randomized withdrawal phase and maintenance phase. The study will last approximately 12 months. While in the study, participants will receive a once daily dose of Upadacitinib that best helps control their disease. During the study participants will be asked to answer questions about their health and medical history. They will also complete physical exams, blood tests, and other questionnaires.

Start Date01 Oct 2026

Sponsor / Collaborator

Baylor College of Medicine

[+2]

NCT07588568

/ Not yet recruitingPhase 2IIT

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).
The main question it aims to answer are:
- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?
Participants will:
* Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib
* Fill out surveys and answer health questions
* Visit the clinic every 4 weeks for checkups and tests

Start Date01 Oct 2026

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+5]

100 Clinical Results associated with Upadacitinib hemihydrate

Login to view more data

100 Translational Medicine associated with Upadacitinib hemihydrate

Login to view more data

100 Patents (Medical) associated with Upadacitinib hemihydrate

Login to view more data

1,900

Literatures (Medical) associated with Upadacitinib hemihydrate

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

Author: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Li, Sitong ; Chen, Xiang ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment

Article

Author: Pastuszczak, Maciej ; Stepinska, Paulina ; Zawadzinska-Halat, Kamila

BACKGROUND:

Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.

OBJECTIVES:

To compare ocular outcomes and conjunctival microbiology in patients with moderate-to-severe AD treated with dupilumab versus upadacitinib.

METHODS:

In this prospective real-world study, adult patients were treated with dupilumab or upadacitinib and evaluated at baseline and after 16 weeks. Ocular assessment included the Ocular Surface Disease Index (OSDI) and Schirmer test. Conjunctival swabs were collected for culture. Dermatological outcomes were assessed using EASI and DLQI.

RESULTS:

Ninety-six patients were included (upadacitinib, n = 52; dupilumab, n = 44). Both treatments significantly improved EASI and DLQI. Conjunctivitis occurred in 39.0% of dupilumab-treated patients and in none of the upadacitinib-treated patients (p < .001). OSDI improved with upadacitinib (-8.3) but worsened with dupilumab (+2.1) (p < .001). Schirmer test results and bacterial colonization did not differ between groups.

CONCLUSIONS:

Dupilumab and upadacitinib showed comparable dermatological efficacy but distinct ocular safety profiles. Dupilumab was associated with more frequent conjunctivitis and worsening ocular symptoms.

566

News (Medical) associated with Upadacitinib hemihydrate

11 Sep 2026

·www.biospace.com

CDR-Life Announces CDR209, a Novel T Cell Engager for Treatment of Axial Spondyloarthritis

Novel M-gager® candidate designed to selectively target TRBV9-positive autoreactive T cells while preserving normal immune function, with potential applicability across HLA-B27-associated autoimmune diseases ZURICH, Switzerland--(BUSINESS WIRE)-- CDR-Life, Inc. , a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced its newest development candidate, CDR209, a novel T cell engager for the treatment of axial spondyloarthritis (axSpA) and potentially other HLA-B27 associated autoimmune diseases. Built on the company's proprietary M-gager® platform, CDR209 is designed to redirect healthy T cells to selectively eliminate TRBV9-positive autoreactive T cells, which have recently been shown to drive disease in many patients with HLA-B27-associated axSpA i . By targeting this small population of pathogenic T cells while preserving approximately 95% of healthy T cells and other immune cells, CDR209 aims to address an underlying driver of disease without the broad immune suppression associated with conventional therapies. "Patients with axial spondyloarthritis continue to need better treatment options," said Christian Leisner, Ph.D., Chief Executive Officer of CDR-Life. "While current therapies have improved disease management, many patients continue to experience active disease despite treatment. CDR209 represents an important step in expanding our M-gager platform into autoimmune disease and reflects our commitment to developing highly selective T cell engagers designed to address disease with greater depth and precision." Axial spondyloarthritis is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints and is estimated to affect up to 2.7 million adults in the United States. ii Although treatment options have expanded over the past two decades, many patients do not achieve adequate disease control with currently available therapies. Standard treatment begins with nonsteroidal anti-inflammatory drugs (NSAIDs) and may progress to biologic therapies such as TNF, IL-17 or JAK inhibitors. Published studies suggest that only about 40–50% of patients with axSpA achieve an ASAS40 response (a standard measure of meaningful improvement in disease signs and symptoms), with currently approved biologic therapies, underscoring the need for additional treatment options. iii “Axial spondyloarthritis, historically referred to as ankylosing spondylitis, often begins early in adulthood and can have a substantial long-term impact on mobility, work and overall quality of life. Although current therapies can control inflammation and symptoms in many patients, they generally require continuous treatment and do not specifically eliminate the immune cells that may be driving the disease,” said Denis Poddubnyy, M.D., Ph.D., Professor of Medicine and Director of the Division of Rheumatology, Temerty Faculty of Medicine, University of Toronto. “There is growing interest in approaches that target selected populations of disease-associated immune cells, such as TRBV9-positive T cells, which appear to play an important role in the immune response underlying axial spondyloarthritis. Selectively removing these cells, while preserving the broader immune system, raises the possibility of interrupting the disease process at a more fundamental level. The longer-term goal is to determine whether such an immunological reset can translate into durable disease control or even treatment-free remission.” In preclinical studies, CDR209 demonstrated high-affinity binding to TRBV9, potent and selective depletion of TRBV9-positive T cells, and no detectable depletion of non-target T-cell populations. The clinical candidate has also demonstrated favorable developability characteristics supporting continued preclinical development. CDR209 expands CDR-Life's growing pipeline of T cell engager therapies for autoimmune diseases and complements the company's oncology portfolio, including CDR404, which is currently being evaluated in a Phase 1 clinical trial in patients with MAGE-A4-positive solid tumors. About CDR209 CDR209 is a first-in-class T cell engager designed to selectively eliminate the TRBV9-positive autoreactive T cells implicated in axial spondyloarthritis. Developed using CDR-Life's proprietary M-gager® platform, CDR209 is intended to preserve the broader immune system while targeting disease-driving cells including deep in tissues. About CDR-Life CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. Our M-gager® platform delivers TCEs against challenging but clean targets through unparalleled binding-specificity. With our first oncology program now in clinical trials, we are advancing a pipeline of potent and selective TCE therapeutics. Our longstanding collaboration with Boehringer Ingelheim on a molecule derived from our M-gager® platform, now in Phase 2, demonstrates the potential of our antibody-derived molecules. The partnership between the companies expanded further in 2025 through a new global licensing agreement to develop a trispecific M-gager for autoimmune diseases. Backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally. Learn more at i Britanova OV, Lupyr KR, Staroverov DB, et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023;29:2731–2736. doi:10.1038/s41591-023-02613-z; Nasonov EL, Mazurov VI, Lila AM, et al. The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA. Dokl Biochem Biophys. 2025;522:387-403. doi:10.1134/S1607672925700140 ii Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care & Research (Hoboken) . 2012;64(6):905-910 iii Adalimumab (ABILITY-1): ASAS40 ≈ 36% at week 12 ( ) Upadacitinib (SELECT-AXIS 2 nr-axSpA): ASAS40 45% at week 14 (AbbVie press release ) Secukinumab: ASAS40 at week 16 were 42% and 33% in the groups that received s.c. secukinumab at the higher and lower doses, respectively ( ) Tofacitinib: ASAS40 at week 16 was 40.6% ( ) Contacts Media: Lauren Arnold LA Communications Lauren@lacommunications.net Investors: Christian Leisner CDR-Life Inc. Christian.Leisner@cdr-life.com

Phase 1Clinical ResultImmunotherapyLicense out/inPhase 2

08 Sep 2026

·www.fiercebiotech.com

Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins

Spyre Therapeutics' three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a win in a phase 2 ulcerative colitis (UC) study. The therapy, dubbed SPY003, met its primary and secondary endpoints in Part A of the Skyline study of 44 UC patients by demonstrating a significant reduction in disease activity and induction of clinical remission, according to a Sept. 8 release . Specifically, SPY003 induced a 10-point reduction from baseline in Robarts Histopathology Index (RHI) score, a measure of disease activity and remission in UC, by Week 12. Secondary endpoints included clinical remission by modified Mayo Score of 20%, used to measure disease severity and treatment response, and endoscopic improvement of 30%. The Skyline program is a two-part induction and maintenance platform trial for patients with moderately-to-severely active UC that consists of three investigational antibodies: SPY001, an anti-α4β7 antibody, SPY002, an anti-TL1A antibody and SPY003. The win for SPY003 comes after SPY002 scored its own success in June, while a positive readout for SPY001 was announced back in April. “With today’s SPY003 data building upon impressive SPY001 and SPY002 results, we have now delivered three potential best-in-class IBD readouts within a span of five months, demonstrating the quality and efficiency of our development organization and strategy,” Spyre CEO Cameron Turtle said in the release. “We believe that these combinations have the potential to deliver an efficacy, safety and dosing profile that meaningfully surpasses today’s standard of care, and we are excited to unveil those data in 2027,” Turtle added. Part A of the Skyline trial consisted of a single dose level for each investigational monotherapy, while Part B will assess the safety and efficacy of two dose levels of the monotherapies and in combinations. Of the 44 patients enrolled in this part of the study, 19 experienced treatment-related adverse events (AEs), although none led to participants discontinuing their treatment. Three of the AEs were categorized as serious, but none of these were considered related to the drug. SPY003 is a half-life extended monoclonal antibody targeting IL-23 for the potential treatment of UC, Crohn’s disease and other inflammatory conditions. IL-23 is a cytokine that upregulates the expansion of pro-inflammatory T cells and activates inflammatory pathways that drive progression of inflammatory bowel disease. UC is a type of inflammatory bowel disease with no cure and characterized by long-lasting inflammation and ulcers in the colon and rectum. The UC space is pretty crowded with several therapies that have varying mechanisms of action, such as Takeda’s anti-integrin antibody Entyvio, AbbVie’s anti-IL-23 antibody Skyrizi and its JAK inhibitor Rinvoq, as well as Johnson & Johnson’s IL-23 inhibitor Tremfya. Spyre’s SPY001 was designed to compete with Takeda’s Entyvio , as it targets the same epitope, but Spyre has touted SPY001 as exhibiting a half-life three times greater than Takeda’s asset. Merck & Co. also recently reported positive phase 3 data from its anti-TL1A antibody tulisokibart, acquired from the $11 billion buyout of Prometheus Therapeutics in 2023.

04 Sep 2026

·allsci.com

AbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart

AbbVie (NYSE: ABBV) completed its acquisition of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per share in cash for a total equity value of approximately USD 10.9 billion. The deal adds a clinical-stage immunology pipeline spanning atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) to AbbVie's existing portfolio, which already includes risankizumab (Skyrizi) and upadacitinib (Rinvoq). The transaction was structured as an all-cash acquisition of all outstanding Apogee common stock, with no disclosed milestone payments or contingent value rights. Both boards had unanimously approved the deal, announced in June 2026, and Apogee's Nasdaq listing ceased prior to market open on the closing date. The primary asset is zumilokibart (APG777), a subcutaneous, half-life extended anti-IL-13 monoclonal antibody in development for moderate-to-severe AD. In the Phase II APEX trial, approximately two-thirds of patients on treatment achieved significant skin clearance at 16 weeks; longer-term maintenance data supported quarterly or twice-yearly dosing regimens. Phase III initiation in AD is planned for the second half of 2026. The dosing interval is the principal differentiation: dupilumab (Dupixent, Sanofi/Regeneron) and tralokinumab (Adbry/Adtralza, Leo Pharma), the most direct competitors in the IL-4/IL-13 pathway space, require biweekly or monthly injections in maintenance. Sanofi's amlitelimab, an OX40L inhibitor with a 12-week dosing interval in Phase III, represents a separate next-generation rival in the same market. Beyond zumilokibart, AbbVie acquires APG273, a fixed-dose combination of zumilokibart and APG333, an anti-thymic stromal lymphopoietin (TSLP) half-life extended antibody targeting respiratory type 2 inflammation. Phase I data for APG333 demonstrated suppression of relevant type 2 inflammatory markers for up to six months after a single dose, supporting quarterly or twice-yearly co-administration in asthma. The TSLP space has attracted competing M&A activity: Upstream Bio's long-acting TSLP antibody advanced toward Phase III following a positive severe asthma trial, and GSK acquired Aiolos Bio to secure a rival TSLP asset, establishing a precedent for large-pharma interest in this mechanism. The acquisition extends a structured M&A program for AbbVie that has also included Capstan Therapeutics for an in vivo anti-CD19 CAR-T platform and Nimble Therapeutics for oral peptide IL-23R inhibitors. Notably, Blackstone Life Sciences committed up to USD 1.3 billion in non-dilutive financing for zumilokibart's Phase III development in May 2026 — weeks before the AbbVie deal was announced — providing an independent data point on the asset's perceived clinical and commercial profile ahead of the acquisition close. Spot something wrong? Report an issue with this article

Phase 1Clinical ResultPhase 3Phase 2Acquisition

100 Deals associated with Upadacitinib hemihydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10994 D11048	Upadacitinib hemihydrate	L04AA44	DB15091

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Alopecia Areata	European Union	AbbVie, Inc.	29 Jul 2026
Alopecia Areata	Iceland	AbbVie, Inc.	29 Jul 2026
Alopecia Areata	Liechtenstein	AbbVie, Inc.	29 Jul 2026
Alopecia Areata	Norway	AbbVie, Inc.	29 Jul 2026
Nonsegmental vitiligo	European Union	AbbVie, Inc.	29 Jun 2026
Nonsegmental vitiligo	Iceland	AbbVie, Inc.	29 Jun 2026
Nonsegmental vitiligo	Liechtenstein	AbbVie, Inc.	29 Jun 2026
Nonsegmental vitiligo	Norway	AbbVie, Inc.	29 Jun 2026
Giant Cell Arteritis	European Union	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Iceland	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Norway	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Polyarticular Juvenile Idiopathic Arthritis	United States	AbbVie, Inc.	26 Apr 2024
Crohn's disease, active moderate	European Union	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Iceland	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Norway	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	European Union	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	Iceland	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pediatric Crohn's Disease	Phase 3	United States	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	China	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Japan	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Australia	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Belgium	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Brazil	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Bulgaria	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Canada	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	France	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Greece	AbbVie, Inc.	08 Aug 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03738397 (Heads Up, Pubmed \| J Dermatolog Treat)	Phase 3	Dermatitis, Atopic	385	Dupilumab	qhawlositi(lahkjmyass) = ywamwxaszj tmqasdblps (orseqvsfgl )	Positive	31 Dec 2026
				Upadacitinib	qhawlositi(lahkjmyass) = xljqicnwgh tmqasdblps (orseqvsfgl )
NCT02782663 (CELEST OLE, CTgov)	Phase 2	Crohn Disease	107	Upadacitinib (Upadacitinib 30 mg)	xmiupoczwx = sbpimtncrw gdqhjcsamg (tyyzvizcea, oluirdlgsu - lqxmdudyog) View more	-	13 Aug 2026
				Upadacitinib (Upadacitinib 15 mg, Then 30 mg)	xmiupoczwx = abicgcsoqm gdqhjcsamg (tyyzvizcea, mqemzvfowe - moeccmqmhd) View more
NCT05814627 (SELECT-SWITCH, Pubmed \| Ann Rheum Dis)	Phase 3	Rheumatoid Arthritis	492	Upadacitinib	ioisbrluug(gvkgmptsvt) = qdyqkatxei bsuxganowo (yaeontvsdx ) View more	Positive	01 Jul 2026
				Adalimumab	ioisbrluug(gvkgmptsvt) = nifiobiguz bsuxganowo (yaeontvsdx ) View more
NCT03569293 \| NCT03607422 (Measure Up 1, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Dermatitis, Atopic	398	Upadacitinib 15 mg	wxhejkskzo(ixkwitfzce) = uvgesfkyjc cqdbxoublp (jfzpylbcnt ) View more	Positive	01 Jul 2026
				Upadacitinib 30 mg	wxhejkskzo(ixkwitfzce) = lzermwoada cqdbxoublp (jfzpylbcnt ) View more
EULAR2026	Not Applicable	Axial Spondyloarthritis	602	Upadacitinib	lgrgtynwod(smfoxtbyuo) = qvqwcqvjth gejnaaecqr (bpxqofndeq ) View more	Positive	11 Jun 2026
				TNFi	lgrgtynwod(smfoxtbyuo) = nfvhbfqnzk gejnaaecqr (bpxqofndeq ) View more
END ZOSTER-J (EULAR2026)	Not Applicable	Rheumatoid Arthritis	69	Methotrexate (MTX) monotherapy	dxggrphzik(lpirtllyks) = cgukhywfnw pldcuomuhw (qipnudsrcw ) View more	Positive	11 Jun 2026
				Upadacitinib monotherapy	dxggrphzik(lpirtllyks) = nmgcgskbbi pldcuomuhw (qipnudsrcw ) View more
NCT04169373 (SELECT-AXIS 2, EULAR2026)	Phase 3	Axial Spondyloarthritis	194	Upadacitinib 15 mg	gcjosrhpba(yprdecyeia) = mksdghatio trxupychhf (dhlkdyqgrx ) View more	Positive	11 Jun 2026
				Placebo	frpiykaxoe(alpascuyyc) = enpodkwnjh buqxyanuyl (cqqzcvtarn )
EULAR2026	Not Applicable	Dermatomyositis	40	Upadacitinib (dermatomyositis)	pnddsldhue(eqbuxyszwa) = figzsnhjar rptqkigewq (hpsbjumpng, 10.35) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Rheumatoid Arthritis	454	Upadacitinib	tjokoefskj(fmehjccftr): RR = 1.3 (95.0% CI, 0.77 - 2.19) View more	Similar	11 Jun 2026
				Tocilizumab
EULAR2026	Not Applicable	Arthritis, Psoriatic \| Rheumatoid Arthritis \| Ankylosing Spondylitis	185	Tofacitinib	otngebmope(mubsdfekrh) = Transient abdominal pain and other gastrointestinal symptoms were most frequent adverse event in all agents. miajvrsdhk (mpqlouudxi ) View more	Positive	11 Jun 2026
				Upadacitinib